<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8688344</article-id><article-id pub-id-type="pmc">2074593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Linch</surname><given-names>D. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vaughan Hudson</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hancock</surname><given-names>B. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hoskin</surname><given-names>P. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>D. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Newland</surname><given-names>A. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Milligan</surname><given-names>D. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stevenson</surname><given-names>P. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>J. K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>MacLennan</surname><given-names>K. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gregory</surname><given-names>W. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vaughan Hudson</surname><given-names>G.</given-names></name></contrib></contrib-group><aff>Department of Haematology and Oncology, University College London Medical School (UCLMS), UK.</aff><pub-date pub-type="ppub"><month>7</month><year>1996</year></pub-date><volume>74</volume><issue>2</issue><fpage>318</fpage><lpage>322</lpage><abstract><p>A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third generation, have been reported to give improved results in single-centre studies. Positive evidence from randomised trials has been lacking, and the British National Lymphoma Investigation therefore commenced a randomised comparison of CHOP vs a third-generation regimen, PACEBOM, in November 1987. A total of 459 eligible patients were entered into the trial: 226 in the CHOP arm and 233 in the PACEBOM arm. Overall, there was no significant difference in outcome between the two arms of the trial. In patients with stage IV disease there was an apparent improvement in survival for those treated with PACEBOM, but considerable caution must be exercised with such subgroup analysis.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00018-0158.tif" xlink:title="scanned-page" xlink:role="318" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00018-0159.tif" xlink:title="scanned-page" xlink:role="319" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00018-0160.tif" xlink:title="scanned-page" xlink:role="320" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00018-0161.tif" xlink:title="scanned-page" xlink:role="321" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00018-0162.tif" xlink:title="scanned-page" xlink:role="322" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

